Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

J&J's Quad HIV Combo Likely To Pass CHMP; EU Market Uptake Is Trickier

Johnson & Johnson's quadruple HIV combination is likely to win a positive recommendation for approval in Europe this week – but clever positioning will be required to secure strong uptake for the combination considering its late entry onto a competitive market place.

Approvals Regulation Infectious Diseases
Advertisement

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Soriot's Future And MYSTIC Data To Dominate AstraZeneca's 2Q

Impending critical data for AstraZeneca's PD-1 inhibitor Imfinzi, which is expected to be the backbone of the company's growing cancer immunotherapy portfolio, and speculation around CEO Pascal Soriot's recent trip to Israel, where it is rumored he met with a rival pharma company about its vacant chief exec role, will be hot topics during the company's second-quarter earnings call this week.

Business Strategies Leadership

Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer

As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.

ImmunoOncology Cancer

Immuno-Oncology Outlook: Bavencio Leads PD-1/L1 Pack In Ovarian Cancer

Merck KGaA/Pfizer's Bavencio is likely to be the first checkpoint inhibitor to gain approval in ovarian cancer but Roche's Tecentriq is hot on its heels. The ovarian cancer pipeline boasts seven other late-stage drugs, including antibody-drug conjugates and small molecules, that are ready to ramp up competition on the market.

Clinical Trials ImmunoOncology

Top Pharma Firms' Sales At $351bn By 2026

Datamonitor Healthcare's latest sector analysis indicates that the pharma industry's 10 biggest companies will add $25.5bn in sales over the next decade.

Commercial Growth

Antibiotics Pipeline Is Lively, But Sponsors Are Fragile

Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.

Infectious Diseases Clinical Trials

Follow The Leader: Looking Across The IO Landscape, An Infographic

While interest in immuno-oncology runs deep across the industry, a handful of companies are leading the pack. Scrip offers a side-by-side look at the IO portfolios for BMS, Merck, Roche and AstraZeneca.

ImmunoOncology Cancer
See All
UsernamePublicRestriction

Register